Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leopoldo Puga

Cardiovascular Disease Bakersfield, CA Medical Doctor

NPI 1659312536 CMS profile 301312

8327 Brimhall Rd Ste 701, Bakersfield, CA 93312

Open in the dashboard

General payments

$9,917

438 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leopoldo Puga of Bakersfield, CA is reported in the CMS Open Payments database as having received $9,917 across 438 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,270 64
2024 General $1,649 84
2023 General $1,985 84
2022 General $1,572 74
2021 General $1,030 51
2020 General $653 32
2019 General $757 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leopoldo Puga
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Leopoldo Puga were reported at $2,270. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Leopoldo Puga Cardiovascular Disease median Middle half National median
2019 $757 $450 $127–$1,392 $163
2020 $653 $242 $77–$751 $114
2021 $1,030 $335 $101–$1,037 $132
2022 $1,572 $395 $121–$1,211 $149
2023 $1,985 $443 $136–$1,283 $160
2024 $1,649 $450 $136–$1,323 $164
2025 $2,270 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,727 45 payments
  2. Novartis Pharmaceuticals Corporation $935 55 payments
  3. AstraZeneca Pharmaceuticals LP $895 51 payments
  4. Merck Sharp & Dohme Corporation $874 43 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $539 31 payments
  6. Boston Scientific Corporation $500 15 payments
  7. Amgen Inc. $472 22 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $465 22 payments
  9. CVRx, Inc. $357 19 payments
  10. Cardiva Medical, Inc. $355 2 payments
  11. Other $2,796 133 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,842 432 payments
  2. Travel and Lodging $1,040 4 payments
  3. Education $35 2 payments
Products named General payments · program years 2019–2025
  1. VERQUVO $1,090 53 payments
  2. AVEIR $1,058 5 payments
  3. FARXIGA $676 38 payments
  4. LifeVest $539 31 payments
  5. LEQVIO $532 23 payments
  6. Repatha $392 18 payments
  7. JARDIANCE $370 18 payments
  8. Barostim Neo System $357 19 payments
  9. Cardiva VASCADE 6/7F VCS $355 2 payments
  10. ENTRESTO $336 28 payments
  11. Other $4,999 245 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 86 drugs

Part D claims

10,479

Median for Internal Medicine: 777

Drug cost

$1,373,035

Median for Internal Medicine: $73,373

Branded share of claims

24.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 624 $536,223
Entresto Sacubitril/Valsartan Brand 335 $320,301
Xarelto Rivaroxaban Brand 131 $106,624
Farxiga Dapagliflozin Propanediol Brand 144 $100,581
Januvia Sitagliptin Phosphate Brand 54 $48,334
Jardiance Empagliflozin Brand 53 $39,636
Brilinta Ticagrelor Brand 30 $25,774
Repatha Syringe Evolocumab Brand 27 $20,437
Repatha Sureclick Evolocumab Brand 24 $19,748
Ozempic Semaglutide Brand 19 $16,916

The 10 drugs with the highest cost, of 86 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$751,809

Of which drugs: $1,572

Medicare patients

1,285

Average age 72

Services billed

7,141

679 women, 606 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 58%
Ischemic heart disease 50%
Arthritis 50%
Heart failure 39%
Chronic kidney disease 38%
Atrial fibrillation 31%
COPD 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 76 308 $1,572

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $216
$216 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $135
$135 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $120
$120 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $90
$90 — —
Repatha
  • Amgen Inc. $88
$88 51 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

438 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record